Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 3/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | DOCK5 | Q9H7D0 | 1/20 | 0.37 |
| ▸ | HTR3A | P46098 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5621549 | 0.86 | CHKA (0.45) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL5622870 | 0.82 | ACHE (0.44) | DRD2DRD3KCNH2 | |
| SCHEMBL5621600 | 0.82 | ACHE (0.44) | DRD2DRD3KCNH2 | |
| SCHEMBL5622795 | 0.80 | PDE2A (0.39) | DRD2DRD3KCNH2 | |
| SCHEMBL14458480 | 0.78 | DRD2 (0.46) | DRD2DRD3KCNH2 | |
| SCHEMBL5620557 | 0.78 | DRD2 (0.46) | DRD2DRD3KCNH2 | |
| SCHEMBL5622611 | 0.78 | DRD2 (0.46) | DRD2DRD3KCNH2 | |
| SCHEMBL5620609 | 0.78 | KMT2A (0.47) | DRD2DRD3KCNH2FAAHHTR3A | |
| SCHEMBL5622208 | 0.77 | DRD2 (0.39) | HCRTR1HCRTR2DRD2DRD3KCNH2 | |
| SCHEMBL5622497 | 0.76 | CYP19A1 (0.45) | DRD2DRD3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070173525-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2007-07-26 | — | — | US | claimed |
| US-20070173525-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2007-07-26 | — | — | US | disclosed |
| US-20070173525-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2007-07-26 | — | — | US | disclosed |
| US-20070173525-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173525-A1 | Tyrosine kinase inhibitors | ABL1, JAK2, ERBB2 | DPP4 926/4885DPP8 842/4885HCRTR1 1413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.